Muscular dystrophy could be the next disease to get whacked by gene therapy
Four boys have received a gene-replacement treatment for muscular dystrophy, and it’s stoking hopes that scientists will cure this disease for good.
What: The biotech company Sarepta, in Cambridge, Massachusetts, said boys who received the gene therapy showed high levels of dystrophin, the protein that’s missing in the terrible disease.
Big deal? You bet. Muscular dystrophy is common, fatal, and currently incurable. But gene therapy might solve it. Sarepta’s stock shot up today by 50 percent.
How they did it: Dystrophin is one of the biggest genes in the human genome. Its size makes it too big to stuff inside a virus, which is needed to get the new gene into the body. The Sarepta team got over this hurdle by working with foreshortened “micro” versions of the gene instead. Others are eyeing CRISPR gene editing as the way to go.
More to come: Sarepta’s study is being carried out at Nationwide Children’s Hospital in Ohio. Two other similar studies, from Pfizer and Solid Biosciences, are also under way.
Deep Dive
Biotechnology
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
How do strong muscles keep your brain healthy?
There’s a robust molecular language being spoken between your muscles and your brain.
The quest to show that biological sex matters in the immune system
A handful of immunologists are pushing the field to take attributes such as sex chromosomes, sex hormones, and reproductive tissues into account.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.